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changed by them and they are so multi-
faceted that it is very difficult to measure
them in any meaningful sense. Yet these
ineffable, immeasurable, uncertain
relationships between doctors and patients
remain very close to the warm fuzzy heart of
general practice and much of its essence.
Iona Heath,
GP, Caversham Group Practice and
Chair of the RCGP International Committee.
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Getting a grip on guidelines:
how to make them more relevant for practice
Evidence-based guideline development can
be seen as one of the major achievements in
efforts to improve patient care in the last
decade. Well developed clinical guidelines
provide professionals, patients, and policy
makers with information on how to manage
health problems appropriately within day-to-
day practice. The development of guidelines
has made an enormous progress in the last
10–15 years with many guideline
development programmes, such as those of
NICE, SIGN, and medical colleges, using
established methods and procedures,
according to AGREE Collaboration criteria.1
New developments related to searching
and grading evidence (SEARCH, GRADE),
and adapting guidelines to local context
(ADAPTE) aim at making guideline
development better and more effective.
Guidelines have had a major impact on care
in general practice in some countries; for
instance, in the Netherlands most problems
seen in general practice are covered by
national evidence-based guidelines
developed by the scientific body with now
around 75% of the decisions in line with
these guidelines.2
An exciting next step in this development is
to link evidence-based guidelines to
incentives for performance, as initiated in the
Quality and Outcomes Framework (QOF). A
worldwide collaboration between guideline
developers has been created with over 70
organisations as members (Guidelines
International Network). A new world of
clinicians, epidemiologists, and professional
guideline developers with their own meetings,
procedures, and vested interests has grown.
This highlights also one of the risks of
guideline development, that is, becoming
increasingly ‘institutionalised’, top-down
driven by research findings, notably
randomised controlled trials, imposed upon
practice. A balanced view of risks and
benefits of clinical guidelines is therefore
needed, in which preferences of patients and
demands of practice and policy, are matched
with the achievements of science.
Against this background, a number of
persistent problems can be observed in
guideline development that come forward in
the paper comparing depression guidelines
from seven different countries, in this issue of
the BJGP.3 One of the problems identified is
that many clinical guidelines still do not yet
meet internationally accepted quality criteria,
as defined in the AGREE instrument.1 For
instance, the rigour of development scores
for the seven studied depression guidelines
ranged from 1–64%.3 In addition,
experiences with guideline development
indicate that there is a risk of substantial bias
in guidelines.3 Appropriate evidence is
lacking for many recommendations and,
even when evidence is available, the final
recommendations for practice are often
largely a reflection of local culture or personal
views of the guideline developers. Guideline
developers in different countries often come
up with different advice for decision making
in practice, partly because they refer to
different, not overlapping sources of
evidence.4,5 Normative and cultural opinions
about the value of specific performance often
play an important role in defining
recommendations for practice without
making these explicit.6,7
Many recommendations in clinical
guidelines aim at ‘ideal patients’, usually
adult patients without any comorbidity, and
are not very well tailored to actual patient
care and real patients. In normal general
practice, many patients, particularly patients
with chronic multi-morbidity, have a
combination of (interacting) problems, which
make appropriate performance and decision
making more complex.8 There is an obvious
development towards integrated care with
increasing collaboration between disciplines,
while most clinical guidelines do not yet
focus on this complexity. A recent publication
relating to GPs’ management of depression
has cast doubts on whether essential
aspects of day-to-day care, notably
comorbidity, have been considered in
evidence-based guidelines and QOF
indicators.9,10 Many clinical guidelines are still
mono-disciplinary, often written by
specialists from tertiary care, who have a
different type of patient in mind.
Guideline development is time consuming
and expensive, about €100 000–200 000 per
guideline, and the question is, if this is cost-
effective. It may be, if guidelines were valid
and had a wide impact on health care.
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However, even well developed evidence-
based guidelines are often not used in day-to-
day care (estimations range from 25–50%).
There are different causes for clinical
guidelines not being used, partly related to
the guidelines themselves. For instance,
some guidelines are written as a handbook on
a clinical topic and not as a concise set of
concrete recommendations for decisions in
day-to-day practice. They often have too
many recommendations, making it difficult for
the user to identify the key-issues and most
important targets. Many do not answer the
crucial questions of patients and practitioners
related to the health problem well, as outlined
by Hegarty et al.3
In a large study (yet unpublished) on the
implementation of chronic obstructive
pulmonary disease (COPD) guidelines in the
Netherlands, we found that improvement
failed, largely because patients did not follow
the advice of their GPs. The guidelines on
COPD do not address this problem of non-
adherence sufficiently. Many guidelines also
lack the tools that should help to make them
work in real practice, such as well-structured
care pathways and well-developed
indicators to measure performance and
change, and focused programmes to
support their implementation.
Clinical guidelines are potentially very
valuable tools to support decision making in
general practice, but some improvements are
required in current guidelines and guideline
development processes to make them more
relevant. They should, for instance, be
focused more on key-issues in patient care,
with direct relevance for both practitioners
and patients; they should take real
(comorbid) patients as a starting point; they
should be developed in less time-intensive
procedures to keep them updated,
presented in more concise formats, and be
combined with quality indicators and support
tools for practice. A priority is better
collaboration between all stakeholders —
clinicians, scientists, patients, policymakers,
and others — to identify jointly the most
important questions, assess the available
evidence, and draw recommendations that
can work under prevailing practice
conditions.11 The limitations and importance
of drawing guidelines for highly different
circumstances under which practitioners
encounter their patients should be
acknowledged. This is even more important
when financial incentives are linked to the
evidence-based guidelines. Such
improvements should lead to guidelines
being able to deliver what they intend: better
care for patients in response to their needs.
Richard Grol,
Director, IQ Healthcare, Radboud University
Nijmegen Medical Centre, Nijmegen,
the Netherlands.
Chris van Weel,
Chair, Department of Family Medicine, Radboud
University Medical Centre, Nijmegen,
the Netherlands.
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Direct access to diagnostic services
Under conventional systems of care,
outpatient clinics see patients referred by a
GP for clinical assessment by a hospital
specialist. Subsequent hospital visits are
arranged to undertake any specialist
diagnostic tests that may be required and
to initiate treatment where necessary. In
other words, the specialist in the outpatient
clinic acts as a gatekeeper to other hospital
resources. Allowing the GP to bypass this
gatekeeper and gain ‘direct access’ to tests
can enable GPs to make more efficient use
of hospital resources and reduce waiting
times for patients.
Direct access to diagnostic services
should reduce outpatient attendance in that
GPs may refer patients for diagnostic
testing without prior consultant
assessment. Waiting time from presentation
to testing is accordingly reduced. If the
patient can be managed by the GP without
subsequent referral to a consultant, waiting
time from presentation to treatment is also
reduced and further outpatient attendance
avoided. However, direct access may
increase demand for testing and lead to less
appropriate referrals with a consequent
reduction in diagnostic yield. It is also
possible that the quality of care will decline
if GPs fail to take appropriate clinical action
in response to test results. All other factors
being equal, the direct cost to hospitals may
be reduced if savings from reduced referral
rates to outpatient clinics are greater than
the costs of providing the direct access
service.
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